

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LIANG *et al.*

Appl. No.: 10/531,049 (Nat'l Phase of
Appl. No. PCT/CN2002/000728)

§ 371 Date: January 17, 2006

For: **A Natural Compound for
Prevention and Treatment of
Diabetes, Process for Preparing
the Same, and Pharmaceutical
Use Thereof** (as amended)

Confirmation No.: 5056

Art Unit: 1615

Examiner: KEYS, Rosalynd Ann

Atty. Docket: 2108.0060000/MAC/DJN

**First Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on January 27, 2006 in connection with the above-captioned application.

Copies of documents **NPL6 to NPL9** are submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document, **NPL7**, cited on Form PTO/SB/08A:

The document **NPL7** was cited in a communication by a foreign patent office in a counterpart foreign application. Submission of an English language version of a search report or other action that indicates the degree of relevance found by the foreign office is provided in satisfaction of the requirement for a concise explanation of relevance. See MPEP 609.04(a). The communication is attached as document **NPL9** on accompanying IDS Form, PTO/SB/09B.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Daniel J. Nevfivy
Agent for Applicants
Registration No. 59,118

Date: June 14, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
684244v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/531,049 (Nat'l Phase of Appl. No. PCT/CN2002/000728)
				Filing Date	January 17, 2006 (§ 371 Date)
				First Named Inventor	LIANG, Jingyu
				Art Unit	1615
				Examiner Name	KEYS, Rosalynd Ann
Sheet	1	of	1	Attorney Docket Number	2108.0060000/MAC/DJN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL6	Narayanan, C.R., <i>et al.</i> , "Pinitol-A New Anti-Diabetic Compound From The Leaves of <i>Bougainvillea Spectabilis</i> ," <i>Current Science</i> 56:139-141, Indian Academy of Sciences (1987)	
	NPL7	Plouvier, V., "Sur la recherche du séquoyitol et du pinitol chez quelques Gymnospermes," <i>Comptes Rendus</i> 245:2377-2379, Elsevier Ltd. (1957)	
	NPL8	STN Database CA, Accession No. 1975:533681, English language abstract for Lee, C.L., <i>et al.</i> , "Inhibitory effect of <i>Taxus mairei</i> heartwood extractives on the curing of unsaturated polyester resins," <i>Mokuzai Gakkaishi</i> 21:249-256, Nihon Mokuzai Gakkai (1975)	
	NPL9	Copy of Official Communication in European Application No. 02 774 265.9, mailed on March 28, 2007	

684243v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.